Skip to main content
Premium Trial:

Request an Annual Quote

Pathway Genomics to Offer Genetic Testing Services to Practice Fusion Members

NEW YORK (GenomeWeb News) – Genetic testing laboratory Pathway Genomics today announced a partnership with Practice Fusion to offer its services to Practice Fusion's network of more than 150,000 medical professionals.

San Francisco-based Practice Fusion provides a free, web-based electronic medical record application to physicians. In a statement, Pathway Genomics Chief Medical Officer Michael Nova said that integrating his firm's services into Practice Fusion's EMR platform is a "critical step" in making actionable genetic information more accessible to physicians and patients.

Pathway conducts the analysis and interpretation of test results at its CLIA genetic testing lab and offers several DNA tests covering diet and exercise, drug response, carrier status, and complex health conditions.

Terms of today's agreement were not disclosed.

The deal follows an announcement in January by San Diego-based Pathway that it had joined Blue Shield's preferred provider organization network.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.